8-K: Actuate Therapeutics Announces Positive Phase 2 Topline Data for Elraglusib in Metastatic Pancreatic Cancer

Actuate Therapeutics reports statistically significant improvement in overall survival in a Phase 2 trial of elraglusib combined with gemcitabine/nab-paclitaxel (GnP) for first-line treatment of metastatic pancreatic cancer.

Summary

• Actuate Therapeutics announced positive topline data from its Phase 2 trial (Actuate-1801 Part 3B) of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC).
• The trial met its primary endpoint, demonstrating a statistically significant improvement in overall survival in the elraglusib/GnP combination arm compared to the GnP control arm.
• The elraglusib/GnP combination arm also showed a substantial improvement in median overall survival since the last data analysis.
• The combination arm demonstrated a favorable risk-benefit profile.
• The company plans to present the topline data at the upcoming ASCO Annual Meeting on May 31, 2025.
• Actuate intends to work with US and EU regulators in the second half of 2025 to advance elraglusib to NDA and registration.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the statistically significant results in the Phase 2 trial, but tempered by concerns about the company's financial stability and the need for additional capital.

Positives

• The Phase 2 trial of elraglusib in combination with GnP met its primary endpoint, showing statistically significant improvement in overall survival for mPDAC patients.
• The combination arm demonstrated a favorable risk-benefit profile.
• The company plans to present the topline data at the ASCO Annual Meeting.
• Actuate is planning to work with regulators to expedite the commercialization of elraglusib.

Negatives

• The company's financial condition raises substantial doubt about its ability to continue as a going concern.
• Actuate requires additional capital to finance its operations beyond the second quarter of fiscal year 2025.
• Failure to obtain necessary capital could force the company to delay, limit, reduce, or terminate its development programs.

Risks

• Preliminary data is subject to change and further interpretation.
• Clinical drug development is lengthy and expensive with uncertain timelines and outcomes.
• Elraglusib may be associated with side effects, adverse events, or other safety risks.
• The company relies on third parties to conduct non-clinical studies and clinical trials.
• Actuate faces significant competition from other biotechnology and pharmaceutical companies.
• The company's ability to fund development activities is uncertain.

Future Outlook

Actuate plans to work with US and EU regulators in the second half of 2025 to map out the path to advancing elraglusib to NDA and registration, aiming to make the drug available to patients as expeditiously as possible.

Management Comments

• Daniel Schmitt, President & Chief Executive Officer of Actuate, stated that there have been no major advances in improving survival in first-line treatment of metastatic pancreatic cancer in over a decade.
• Daniel Schmitt believes that demonstrating statistically significant increases in both median overall survival and percent of patients reaching one-year survival and beyond, along with a favorable risk-benefit profile, further demonstrates elraglusib's potential to shift the treatment paradigm in mPDAC.

Industry Context

The announcement addresses a significant unmet need in the treatment of metastatic pancreatic cancer, where there have been limited advancements in survival rates over the past decade; the success of elraglusib could position Actuate Therapeutics as a key player in this therapeutic area.

Comparison to Industry Standards

• Gemcitabine and nab-paclitaxel (GnP) is a common chemotherapy regimen used as a standard of care for first-line treatment of metastatic pancreatic cancer.
• Companies like Celgene (now part of Bristol Myers Squibb) with Abraxane (nab-paclitaxel) have established this standard.
• The press release highlights that there have been no major advances in improving survival in first-line treatment of metastatic pancreatic cancer in over a decade, suggesting that the current standard of care has limitations.
• Actuate's elraglusib, when combined with GnP, aims to improve upon this standard by demonstrating statistically significant increases in both median overall survival and the percentage of patients reaching one-year survival.

Stakeholder Impact

• Positive impact on patients with metastatic pancreatic cancer due to potential new treatment option.
• Potential positive impact on shareholders if elraglusib is successfully commercialized.
• Potential impact on employees related to job security and company growth.

Next Steps

• Presentation of topline data at the ASCO Annual Meeting on May 31, 2025.
• Working with US and EU regulators in the second half of 2025 to advance elraglusib to NDA and registration.

Key Dates

Keywords

elraglusib, pancreatic cancer, metastatic pancreatic ductal adenocarcinoma, mPDAC, Actuate Therapeutics, GSK-3, gemcitabine, nab-paclitaxel, GnP, clinical trial, overall survival, ASCO, FDA, EMA